Advanced in Acquired Agranulocytosis

Dr. Thomas M. Cosgriff

Hematology Oncology | Hematology | Oncology
4204 Houma Blvd, Floor 2, 
Metairie, LA 
Accepting New Patients
Advanced in Acquired Agranulocytosis
4204 Houma Blvd, Floor 2, 
Metairie, LA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Thomas Cosgriff is a Hematologist Oncology specialist and a Hematologist in Metairie, Louisiana. Dr. Cosgriff is rated as an Advanced provider by MediFind in the treatment of Acquired Agranulocytosis. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Pleuropulmonary Blastoma, and Colorectal Cancer. Dr. Cosgriff is currently accepting new patients.

His clinical research consists of co-authoring 6 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in LA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Louisiana Healthcare Connections
  • HMO
  • MANAGED MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

4204 Houma Blvd, Floor 2, Metairie, LA 70006

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Enrollment Status: Completed
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drugs: Elacestrant, Standard of Care
Study Phase: Phase 3
A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal and Genitourinary Tumors
A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal and Genitourinary Tumors
Enrollment Status: Completed
Publish Date: November 18, 2023
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 2b/3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Clonidine Mucoadhesive Buccal Tablet to Placebo to Prevent Chemoradiotherapy-induced Severe Oral Mucositis in Patients With Oropharyngeal Cancer
A Phase 2b/3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Clonidine Mucoadhesive Buccal Tablet to Placebo to Prevent Chemoradiotherapy-induced Severe Oral Mucositis in Patients With Oropharyngeal Cancer
Enrollment Status: Terminated
Publish Date: May 31, 2023
Intervention Type: Drug
Study Drug: Clonidine HCl Mucoadhesive Buccal Tablet
Study Phase: Phase 2/Phase 3
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Enrollment Status: Completed
Publish Date: March 20, 2023
Intervention Type: Drug
Study Drugs: CB-839, Cabozantinib
Study Phase: Phase 2
Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus Cyclophosphamide, Doxorubicin and Vincristine (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS)
Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus Cyclophosphamide, Doxorubicin and Vincristine (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS)
Enrollment Status: Completed
Publish Date: October 28, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 4 Less Clinical Trials

6 Total Publications

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.
Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: February 02, 2018
Similar Doctors
Experienced in Acquired Agranulocytosis
Dr. Ronald D. Leblanc
Hematology Oncology | Hematology | Oncology
Experienced in Acquired Agranulocytosis
Dr. Ronald D. Leblanc
Hematology Oncology | Hematology | Oncology

Ochsner Clinic LLC

1514 Jefferson Hwy, 
New Orleans, LA 
 (4.2 miles away)
504-842-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ronald Leblanc is a Hematologist Oncology specialist and a Hematologist in New Orleans, Louisiana. Dr. Leblanc is rated as a Distinguished provider by MediFind in the treatment of Acquired Agranulocytosis. His top areas of expertise are Childhood Iron Deficiency Anemia, Paget Disease of the Breast, Familial Colorectal Cancer, and Clear Cell Sarcoma. Dr. Leblanc is currently accepting new patients.

Experienced in Acquired Agranulocytosis
Dr. Shaista H. Faruqui
Hematology Oncology | Hematology | Oncology
Experienced in Acquired Agranulocytosis
Dr. Shaista H. Faruqui
Hematology Oncology | Hematology | Oncology
5320 Dijon Dr, 
Baton Rouge, LA 
 (61.7 miles away)
225-769-2161
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Shaista Faruqui is a Hematologist Oncology specialist and a Hematologist in Baton Rouge, Louisiana. Dr. Faruqui is rated as a Distinguished provider by MediFind in the treatment of Acquired Agranulocytosis. Her top areas of expertise are Idiopathic Neutropenia, Chronic Familial Neutropenia, Immune Thrombocytopenic Purpura (ITP), and Adult Immune Thrombocytopenia. Dr. Faruqui is currently accepting new patients.

Experienced in Acquired Agranulocytosis
Dr. Carrie L. Marquette
Hematology Oncology | Hematology | Oncology
Experienced in Acquired Agranulocytosis
Dr. Carrie L. Marquette
Hematology Oncology | Hematology | Oncology

Mary Bird Perkins Cancer Center

4950 Essen Ln, Suite 200, 
Baton Rouge, LA 
 (61.3 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Carrie Marquette is a Hematologist Oncology specialist and a Hematologist in Baton Rouge, Louisiana. Dr. Marquette is rated as a Distinguished provider by MediFind in the treatment of Acquired Agranulocytosis. Her top areas of expertise are Paget Disease of the Breast, Inflammatory Breast Cancer, Upper Tract Urothelial Carcinoma (UTUC), and Colorectal Cancer. Dr. Marquette is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Cosgriff's expertise for a condition
ConditionClose
      View All 13 Advanced Conditions
      View All 87 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile